Mobile website
Archive > Volume 24 Issue 11 > 2017,24(11):1281-1286. DOI:10.3872/j.issn.1007-385X.2017.11.007 Prev Next
Clinical Research
Comparation of clinical efficacy of single- unit and double- unit nonrelative cord blood transplantation for therapy of hematonosis
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To comparatively analyze clinical efficacy of single- unit and double- unit nonrelative cord blood transplantation for treatment of hematologic diseases. Methods: Clinical data of the 185 patients received single-unit umbilical cord blood transplantation (SU-UCBT) and the 66 patients received double-unit umbilical cord blood transplantation (DU-UCBT) in 8 domestic transplant centers during 2006 to 2016 were retrospectively analyzed.It was compared that implantation rates, implantation time of neutrophil granulocyte and platelet between SUUCBT and DU-UCBT, as well as occurrence of acute graft vs host disease (aGVHD) and survival rates of the patients with malignant hematonosis and with non malignant hematonosis after SU-UCBT and DU-UCBT. Results:Implantation rates of the patients received SU-UCBT and DU-UCBT were 78.9% and 70.7% respectively, among them implantation rates of the patients with malignant hematonosis were 89.1% for SU-UCBT and 82.5% for DUUCBT as well as implantation rates of the patients with non malignant hematonosis were 64.0% for SU-UCBT and 53.8% for DU-UCBT, implantation rates of SU-UCBT and DU-UCBT were similar (P>0.05). In the patients received SU-UCBT and DU-UCBT, median implantation times of neutrophil granulocyte were all 18 d, median implantation times of platelet were 40 d and 27 d respectively, the difference was not remarkable (P>0.05). Incidence rates of aGVHD at I, II, III, IV grades in the patients received SU-UCBT and DU-UCBT were 22.6%, 22.6%, 8.2%,12.3% and 21.3%, 14.9%, 10.6%, 10.6% respectively, all of the differences were not evident (all P>0.05). Median survival time in the recipients of SU-UCBT and DU-UCBT were 1 460 d (17~2 200 d) and 988 d (21~2 200 d), and their cumulative survival rate of 6 years were respectively 42.5% and 40.4%, all differences were not obvious (P>0.05). Conclusion: Between the patients successfully received SU-UCBT and DU-UCBT, implantation times of neutrophil granulocyte and platelet, incidence rate of aGVHD, survival time and cumulative survival rate of 6 years were not significant, which suggests that DU-UCBT could be a safe and effective selection of UCBT. However, the evaluation system of SU-UCBT and DU-UCBT still needs to be perfected and implantation mechanism of DUUCBT needs to make a thorough inquiry, so as to scientifically guide selection of UCBT.
Keywords:
Project Supported:
Project supported by the Natural Science Foundation of Shanghai Municipality（No. 16ZR1429200）, the Special Research and Development Platform Foundation of Shanghai Science and Technology Commission（No.16DZ2293000）, the Patent Pilot Enterprise Program 2016 of Shanghai（No.001083816000041）, and the Special Development Foundation for Key Project of Zhangjiang National Independent Innovation Demonstration Area of Shanghai （No. ZJ2017-ZD-010）
Clc Number:
